A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma by Fontanini, G et al.
A high vascular count and overexpression of vascular endothelial
growth factor are associated with unfavourable prognosis in
operated small cell lung carcinoma
G Fontanini*
,1, P Faviana
3, M Lucchi
2, L Boldrini
1, A Mussi
2, T Camacci
3, MA Mariani
2, CA Angeletti
2,
F Basolo
1 and R Pingitore
3
1Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, via Roma 57, 56126 Pisa, Italy;
2Department of Cardio-
Thoracic Surgery, University of Pisa, via Roma 57, 56126 Pisa, Italy;
3Department of Surgery, University of Pisa, via Roma 57, 56126 Pisa, Italy
It has been widely demonstrated that neo-angiogenesis and its mediators (i.e. vascular endothelial growth factor), represent
useful indicators of poor prognosis in non small cell lung carcinoma. In order to verify whether neovascularization and vascular
endothelial growth factor may be considered useful markers of clinical outcome also in the small cell lung cancer subgroup, we
retrospectively investigated a series of 75 patients with small cell lung carcinoma treated by surgery between 1980 and 1990.
Immunohistochemically-detected microvessels and vascular endothelial growth factor expressing cells were signiﬁcantly
associated with poor prognosis, as well as with nodal status and pathological stage. In fact, patients whose tumours had
vascular count and vascular endothelial growth factor expression higher than median value of the entire series (59 vessels per
0.74 mm
2 and 50% of positive cells, respectively), showed a shorter overall and disease-free survival (P=0.001, P=0.001;
P=0.008, P=0.03). Moreover, the presence of hilar and/or mediastinal nodal metastasis and advanced stage signiﬁcantly
affected overall and disease-free interval (P=0.00009, P=0.00001; P=0.0001, P=0.00001). At multivariate analysis, only vascular
endothelial growth factor expression retained its inﬂuence on overall survival (P=0.001), suggesting that angiogenic
phenomenon may have an important role in the clinical behaviour of this lung cancer subgroup.
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Small cell lung cancer (SCLC) represents one of the most aggressive
subgroups of lung cancer, and, despite its initial sensitivity to
chemotherapy, most patients with this type of cancer die of meta-
static disease in less than 2 years from diagnosis (Brigham et al,
1978). In the last two decades a large number of clinical studies
have indicated that the angiogenic pattern may be a useful indica-
tor of clinical outcome of tumours, including lung cancer
(Weidner, 2000). In fact, much data has shown that the number
of microvessels in the tumour area, as an index of neo-angiogen-
esis, correlates to an increased risk of metastatic disease and a
worse overall survival (OS) (Macchiarini et al, 1992; Apolinario
et al, 1997; Fontanini et al, 1997a). A number of factors are known
to stimulate new vessel formation, of which vascular endothelial
growth factor (VEGF) is the most commonly expressed in human
tumours (Ferrara, 1995). VEGF has been shown to increase tumour
growth and angiogenesis in vivo in a nude mice model (Ferrara et
al, 1993; Zhang et al, 1995). Similarly, anti-VEGF antibodies have
the ability to inhibit the growth and dissemination of several
tumour cell lines in nude mice (Kim et al, 1993).
Recent studies in NSCLC have shown that both vascular count
and VEGF expression may inﬂuence progression and clinical
outcome of the tumours (Fontanini et al, 1997a,b, 1999). More-
over, some interesting data indicate a putative genetic control of
neo-angiogenesis by genes involved in the proliferative/apoptotic
balance (i.e. p53 and bcl-2) (Bouck, 1996; Fontanini et al,
1997c). There is also evidence that inhibition of angiogenesis limits
tumour growth by promoting apoptosis (Holmgreen et al, 1995).
SCLC is rarely treated by surgery, and, as a consequence, not
enough data are available for an exhaustive biological characteriza-
tion of this type of cancer. Recent analysis has correlated the
clinical outcome of SCLC series to vascular count and VEGF serum
levels, although discrepancies have been observed in the results
obtained in these studies (Salven et al, 1998; Eerola et al, 2000).
In order to investigate the role of neo-angiogenesis in the
outcome of SCLC, we analyzed vascular count, VEGF expression
and p53 pattern in a series of resected SCLC, with interesting
results from a prognostic point of view. The association we found
in our study between VEGF protein expression and outcome is
very suggestive of a putative role of this factor in the development
and progression of the SCLC subgroup, although no conﬁrmatory
data are now available. Despite progression in surgery and
chemotherapy, prognosis of SCLC remains unfortunately extremely
bad, and new therapeutic approaches would be hoped for. In this
sense, the ﬁnding of new biologic factors related to progression and
poor outcome may represent a useful target of innovative thera-
peutic tools, such as anti-angiogenic therapies. In this respect,
SCLC may be an ideal ﬁeld in which to test new anti-angiogenic
therapies in association with conventional chemotherapies.
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Patients
Seventy-ﬁve SCLC patients who had undergone curative surgical
resection at the Service of Thoracic Surgery, University of Pisa,
between 1980 and 1990, were analyzed. There were 72 males and
three females (mean age 61.7 years, median 62 years, range 34–
75 years). All the patients underwent a complete preoperative
staging. This included: a detailed history and a physical examina-
tion, the evaluation of the Performance Status according to
Karnofsky, a complete blood count and biochemical proﬁle, cardiac
and pulmonary function tests, chest X-ray, bronchoscopy,
computed tomography of chest, the upper abdomen and brain,
abdominal ultrasonography, bone scan, Gallium-67 scan, bilateral
bone marrow biopsy and aspiration. Preoperative mediastinoscopy
was not routinely performed where there was an absence of
Gallium up-take on the mediastinum and no bulky mediastinal
lymph-node involvement was evident. All the patients received
surgery as their ﬁrst line therapy, followed by adjuvant chemother-
apy and, in the cases of hilar or mediastinal involvement, also by
radiotherapy. According to Tumour-status, there were 16 T1, 48
T2, and 11 T3; 41 patients did not show nodal metastasis at the
moment of diagnosis, whereas 34 showed hilar and/or mediastinal
metastatic involvement. Data on clinical behaviour were available
in all of the 75 cases (median follow-up 109.6 months, range
25–222). Twenty-nine of the patients were alive at the moment
of analysis, whereas 46 were dead. Tumours were classiﬁed in
accordance with the World Health Organization (WHO, 1982)
classiﬁcation and within the guidelines of the American Joint
Committee for Cancer Staging (AJCCS, 1992).
Immunohistochemistry
Microvessel detection and counting The method of microvessel
detection and counting (MVC) has been described previously
(Fontanini et al, 1997a). Brieﬂy, intratumour microvessels were
highlighted with anti-CD34 Mab (QB-END 10, Novocastra Labora-
tories, Newcastle, UK) diluted 1:100, after heating the sections in a
microwave oven twice for 5 min at 700 W in citrate buffer
(pH 7.6). Biotinylated anti-mouse IgG (Vector, Burlingame, CA,
USA) was applied for immunoreaction, followed by detection using
the ABC method. In all cases, MVC was determined independently
by two pathologists. Each pathologist evaluated the slides without
any knowledge of the counts made by the other pathologist and
of the clinical outcome of the patients. No signiﬁcant differences
in MVC were found between the two observers. In fact, the counts
from the two pathologists showed a very good correlation (r=0.98;
two-sided P=0.0001). When conﬂicting data were obtained, we
used mean values. A single microvessel was deﬁned as any brown,
immunostained endothelial cell that was separated from adjacent
microvessels, tumour cells, and connective tissue elements. Each
sample was examined by each pathologist, who identiﬁed the three
most intense regions of neovascularization under low microscopic
power (610 objective lens and 610 ocular lens). An 6250 field
(625 objective lens and 610 ocular lens; 0.74 mm
2 per ﬁeld) in
each of these three areas was then counted, and the average count
of the three ﬁelds was recorded. Large vessels with thick, muscular
walls were excluded from the counts. The presence of a lumen was
not required to identify a microvessel. MVCs were categorized as a
dichotomous variable (low vs high MVC). In the dichotomous cate-
gorization a count of 59 microvessels (the median value obtained
in this series) was used as the cut-off point to distinguish a low
MVC from a high MVC.
VEGF expression In 53 out of 75 of the cases, according to the
availability of the tumoural material, immunostaining for VEGF
was performed using the ABC method in formalin-ﬁxed, paraf-
ﬁn-embedded tissue samples. Sections were dewaxed in xylen,
taken through ethanol, and then incubated with 0.3% hydrogen
peroxidase in methanol for 10 min to block the endogenous perox-
idase activity. After washing with phosphate-buffered saline (PBS)
and incubation for 30 min with 10% normal goat serum, the
sections were incubated overnight with anti-VEGF monoclonal
antibodies (SantaCruz Biotechnology, Inc., Santa Cruz, CA, USA,
dilution 1:50). Anti-VEGF is raised against a synthetic peptide
corresponding to amino acid residues 1 to 191 of human VEGF;
it recognizes the 165, 189 and 121 amino splicing variants of
VEGF. After the primary antibodies, biotynilated anti-rabbit IgG
(Vector Laboratories, Burlingame, CA, USA) were applied and
followed by detection using the ABC method (Vector Laboratories,
Burlingame, CA, USA). Light counterstaining was performed with
haematoxylin. Normal rabbit immunoglobulin G substituted the
primary antibody as negative controls. VEGF expression was eval-
uated as percentage of positive cells in a total of at least 1000
tumour cells. Tumour sections with no VEGF immunoreactive cells
were considered as negative. The median values of the series (50%
of positive) was used as cut-off values to distinguish low from high
VEGF expressing tumours.
P53 expression As well as VEGF expression, the p53 protein
immunostaining was assessed in formalin-ﬁxed and parafﬁn-
embedded tissue samples using immunohistochemistry. NCL-
DO7 anti-p53 monoclonal antibody (Novocastra Laboratories,
New Castle, UK) was used to detect the p53-altered protein
(1:250 of dilution). The avidin-biotin peroxidase method was used
by developing immunoreaction with Diaminobenzidine. Simulta-
neous staining of a known p53 positive case was employed as
positive control for p53. Incubation of parallel slides omitting
the ﬁrst antibody was performed as negative control. The count
of p53 immunoreactive cells was made by scoring a minimum of
ﬁve high – power ﬁelds (HPFs) (406 objective lens) and counting
the number of immunoreactive cells out of the total of epithelial
cells analyzed in each ﬁeld. The 5% of positive cells was used as
cut-off value to distinguish negative from positive tumours.
Statistical analysis
All statistical analyses were carried out using the Statistica and
SPSS softwares. Univariate analysis was performed by modelling
Kaplan–Meier survival curves. The Log-rank test was used to eval-
uate the statistical signiﬁcance of differences in survival
distributions among prognostic groups. Multivariate analysis was
carried out by use of the Cox proportional-hazard model. The
Cox model was ﬁrst used to select from among variables that
signiﬁcantly affected survival in univariate analysis, and then from
among those variables whose prognostic role was independent.
RESULTS
Clinico-pathological parameters and OS
Among the clinico-pathological parameters, metastatic nodal-invol-
vement (P=0.00009), and advanced stage (P=0.0001) were
signiﬁcantly associated with a worse overall survival. No association
was found between bad prognosis and tumour-status (Table 1). A
similar statistically-signiﬁcant association was observed between
these characteristics and disease-free survival (data not shown).
Figure 1 shows Kaplan–Meier survival plots generated on the basis
of nodal status (Figure 1A), and stage (Figure 1B).
Vascular count and outcome in SCLC
The number of microvessels, evaluated as mean in the three areas
of each tumour with most intense vascularization, showed a mean
of 63.4 vessels and a median value of 59 vessels (range 14–170
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median value of 59 microvessels as the cut-off point), was a highly
signiﬁcant predictor of both overall survival (Table 1; P=0.001) and
of disease-free survival (data not shown). Figure 2 shows Kaplan–
Meier survival plots generated on the basis of low and high vascu-
lar count (Figure 2A).
VEGF and p53 expression and outcome in SCLC
VEGF protein expression, evaluated as low and high on the basis of
median value of the series (mean 40.1, range 0–90%), signiﬁcantly
affected overall (P=0.0008) and disease-free survival. Figure 2
shows Kaplan–Meier survival plots generated on the basis of low
and high VEGF expression (Figure 2B). No statistical association
was found between p53 alterations and overall survival. In fact,
tumours expressing p53 protein failed to inﬂuence the clinical
behaviour of the disease (P=0.1). Furthermore, no association
was found between p53 alterations, vascular count and VEGF
expression (P=0.6; P=0.8) (data not shown).
Vascular count, VEGF expression and clinico-pathological
parameters
When we analyzed the relationship between vascular count and
VEGF expression, clinico-pathological parameters such as sex and
age of patients, tumour-status, nodal-status and stage, we were
unable to ﬁnd any statistical association among these variables
(data not shown). Moreover, no signiﬁcant differences were found
between MVC and VEGF expression and site of tumours.
Multivariate analysis
A multivariate analysis was performed to evaluate the independent
prognostic role of MVC after adjusting for other signiﬁcant covari-
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Table 1 Univariate survival analysis
Features No. of patients Overall survival P
a
Sex
Male 72 0.5
Female 3
Age
462 30 0.06
462 45
Tumour status
T1 16 0.5
T2 48
T3 11
Node status
N0 41 0.00009
N1-2 34
Stage
S1 35 0.0001
S2-3 40
MVC
Low 38
High 37 0.001
VEGF
Low 31 0.008
High 22
aLog-rank test.
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Figure 1 Kaplan–Meier OS estimates in relation to Nodal Status (A)
and Stage (B).
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Figure 2 Kaplan–Meier OS estimates in relation to MVC (A) and VEGF
expression (B). A MVC of 59 microvessels was the median cut-off in the
series of 75 SCLC patients for considering low or high tumour angiogenesis.
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analysis were introduced into a Cox proportional-hazard model
(Table 2). At the end of the stepwise process, only VEGF expres-
sion maintained its independent prognostic inﬂuence on overall
survival (P=0.01). In this analysis, vascular count failed to show
any independent inﬂuence on overall survival (OS).
DISCUSSION
The importance of tumour angiogenesis in tumour development
and progression has been revealed in recent years. Several studies
(revised in Weidner and Folkman, 1996) have suggested that
MVC (as a measure of tumour angiogenesis) is a signiﬁcant predic-
tor of increased risk of metastatic disease and worse OS in several
types of human cancer, including lung cancer. However, relatively
few, and no conclusive reports have been published on the prog-
nostic signiﬁcance of MVC in lung cancers (Macchiarini et al,
1992; Harpole et al, 1996; Giatromanolaki et al, 1996), although
in the NSCLC subgroup some important results have been
obtained (Fontanini et al, 1997a). Neo-angiogenesis is under the
control of several growth factors and cytokines (Bicknell and
Harris, 1991), and the imbalance between stimulating and inhibit-
ing factors is responsible for activating the angiogenic potential of
the tumours. VEGF plays a crucial role in the control of angiogen-
esis both in physiological and pathological situations (Shibuya,
1995), including tumour development and progression. It is mito-
genic and angiogenic for endothelial cells, and it can also increase
vascular permeability.
A number of tumour cells in humans have been seen to express
higher levels of VEGF mRNA compared to normal tissue (Brown et
al, 1993; Plate et al, 1993; Abu-Jawdeh et al, 1996; Yoshiji et al,
1996), suggesting an association of VEGF with a malignant pheno-
type; furthermore, an elevated VEGF expression has also been
correlated to a worse prognosis in cancers such as gastric (Maeda
et al, 1996; Takahashi et al, 1996), colonic (Takahashi et al,
1995) and lung carcinomas (Mattern et al, 1995; Ohta et al,
1996; Fontanini et al, 1997b, 1999).
Small cell lung carcinomas represent a subgroup of lung cancer
which substantially differ from the non-small cell subtype. In fact,
the behaviour of this group of cancers is extremely bad, despite its
initial sensitivity to chemotherapy. An exhaustive biological charac-
terization of SCLC is difﬁcult because of the different therapeutic
approach usually employed in this type of tumour: SCLC is rarely
treated by surgery, and most centres have few specimens on which
to perform a biological characterization. Previously, we published
our surgical experience and our policy in the clinical selection of
patients for a multimodality treatment including surgery in
SCLC-limited disease (Lucchi et al, 1997). Surgery can be applied
as part of a combined treatment in patients with limited SCLC,
selected on the basis of TNM staging. Moreover, despite conven-
tional imaging and invasive procedures (mediastinoscopy etc.),
the clinical prediction of lymphnodal involvement is unsatisfactory,
with about 40% of more advanced disease at operation. This is the
major obstacle in the correct planning of the multimodality treat-
ment of limited-disease SCLC, and the reason for it’s being
inappropriate to compare the results of surgical treatments with
the chemo-radiotherapy and neoadjuvant treatments. In order to
verify the role of angiogenic phenomenon also in SCLC, as we
had previously performed in a large series of non-small cell lung
tumours (Fontanini et al, 1997a,b,c), a series of 75 SCLC was
investigated, with particular reference to vascular count, VEGF
and p53 expression. In our series we observed that nodal metastasis
and tumour stage were important predictors of poor prognosis, as
already reported in previous studies (Shepherd et al, 1993).
As regards vascular count, we observed that a higher number of
microvessels (higher than median value of the series) in the most
intense area of neovascularization signiﬁcantly affected overall
and disease-free survival. However, although exciting, these ﬁnd-
ings are in contrast with results recently presented by Eerola et al
(2000). In a series of 56 SCLC they failed, in fact, to demonstrate
any signiﬁcant association between outcome and microvessel
density. This discrepancy may be mostly due to a different metho-
dology used for detecting microvessels in tumour areas. Eerola et al
(2000) in fact, immunostained their samples by an anti-FVIII poly-
clonal antibody, that, although very speciﬁc, may be a bit less
sensitive than the anti-CD34 monoclonal antibody we used, and
thus causing a misinterpretation of the number of microvessels.
A median value of nine microvessels per HPF was used by the
authors for distinguishing a low from a high vascular density,
dramatically far from the median value we found using CD34
monoclonal antibody in our series of cancers. However, also from
our observations we believe that vascular density in SCLC has a
different prognostic impact in comparison with vascular density
in NSCLC. Indeed, in multivariate analysis, vascular count did
not retain its inﬂuence on OS also in our study. However, an inter-
esting aspect of our paper is related to the expression of VEGF,
which represents one of the most important factors of vascular
development and growth. Previous results of ours demonstrated
that both protein and mRNA VEGF expression were strictly asso-
ciated with prognosis in the NSCLC subgroup (Fontanini et al,
1997b, 1999). In our current study we observed that a high VEGF
expression was signiﬁcantly associated with poor prognosis and,
most important, that in multivariate analysis VEGF expression
retained its prognostic signiﬁcance on OS. Interestingly, recent data
from Salven et al (1998) in SCLC showed that pre-treatment serum
levels of VEGF were associated with poor response to treatment
and unfavourable survival in patients treated with combination
chemotherapy with or without interferon. VEGF is an important
mediator of tumour-induced angiogenesis and represents a poten-
tial target for innovative anticancer therapies. Starting from this
concept, and with it’s having recently been demonstrated in experi-
mental models that anti-VEGF treatment augments tumour
radiation response and the efﬁcacy of cancer immunotherapy
(Gabrilovich et al, 1999; Lee et al, 2000), the evaluation of VEGF
and its receptors may represent a useful aim in drawing up a
correct therapeutic proﬁle of SCLC patients. In several animal
models, neutralizing anti-VEGF antibodies have shown encoura-
ging inhibitory effects on solid tumour growth, ascites formation
and metastatic dissemination. Several of these anti-VEGF therapies
are currently being tested in clinical trials in cancer patients. For
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Table 2 Cox-proportional regression model of overall survival
95% CI
c
Variables Beta SE
a of Beta P RR
b Lower Upper
Node status 0.193 0.358 0.58 1.21 0.60 2.45
Stage 0.521 0.400 0.19 1.68 0.76 3.69
MVC 0.364 0.389 0.34 1.43 0.67 3.08
VEGF expression 0.922 0.388 0.01 2.51 1.17 5.38
aSE=standard error of beta;
bRelative risk;
cConﬁdence interval.
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proﬁle of a tumour seems very interesting, particularly in those
cases in which pharmacological approaches represent an important
modality of treatment.
As regards p53 protein alterations, we did not observe in 51 of
the cases analyzed any association between these alterations and
vascular count and/or VEGF expression, although a high percen-
tage of p53 mutations have been reported to be very frequent
also in SCLC (Takahashi et al, 1991; Levin et al, 1994). Probably
in this type of cancer, the genetic regulation of neo-angiogenesis
is different from what we observed in the NSCLC subgroup,
suggesting the possibility of more complex mechanisms and multi-
ple interactions of several mediators.
Taken together, these data suggest the essentiality of further
analyzing the complex phenomenon of neo-angiogenesis also in
SCLC, in order to determine if in this model the vascular network
and/or its regulators may modify in some way the behaviour of this
type of cancer, and whether, in SCLC, neo-angiogenesis may repre-
sent an ideal ﬁeld in which to test new anti-angiogenic drugs in
association with chemotherapy.
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